TP53 and female reproductive system neoplasm: Our study also demonstrated p16 overexpression in approximately half of the tumors, in line with previous characterizations in TNBC cohorts.33, , , ‐37 P53 expression, typically defined as any staining above either 1% or 10%, has been shown in 44–71% of tumors among TNBC cohorts.33,38, ‐40 Using the p53 IHC interpretation guidelines outlined by Kang and colleagues in their evaluation of gynecologic tumors, our study identified a p53 mutant immunophenotype in 78% of tumors.